Benchmark Keeps Buy Rating on Alibaba (BABA) Despite Challenges
Benchmark noted that the company could face near-term margin pressure because of investments in Food Delivery and Instant Retail services. This led the firm to reduce its Q1 fiscal 2026 and fiscal year 2026 earnings estimates.
Christopher Penler / Shutterstock.com
Benchmark sees this increase in investment by Alibaba Group Holding Limited (NYSE:BABA) as defensive, to respond to JD.com, Inc. (JD) entering the market and making some early market share gains in these segments.
Despite the near-term pressure, the firm pointed out strategic benefits for Alibaba Group Holding Limited (NYSE:BABA) as it can improve and reposition its core e-commerce strategy with a more integrated retail ecosystem approach, which could help the company grow in the long run.
Alibaba Group Holding Limited (NYSE:BABA) is a Chinese multinational technology company focused on e-commerce, retail, AI, digital media and entertainment, cloud, and technology.
While we acknowledge the potential of BABA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Performing Stocks in the Last 6 Months and 12 Most Owned Stocks by Hedge Funds So Far in 2025.
Disclosure: None. This article is originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Palantir Explodes 525%--CTO Becomes Billionaire, Insiders Dump Billions
Palantir Technologies (NASDAQ:PLTR) has been on an absolute tearup 525% over the past yearmaking it the top gainer in the S&P 500 by percentage. That rally just turned Chief Technology Officer Shyam Sankar into a billionaire, joining co-founders Alex Karp, Peter Thiel, and Stephen Cohen at the top of the leaderboard. Shares recently hit an all-time high of $158.80 after the company locked in a massive 10-year U.S. Army agreement worth up to $10 billion. The AI and defense software specialist is also riding a tidal wave of retail investor demandranking third in net retail buying activity behind only Tesla (NASDAQ:TSLA) and Nvidia (NASDAQ:NVDA), per June data from Vanda Research. Sankar's journey is a classic tech underdog story. He joined Palantir as employee #13 after stints at Xoom Corp. and Stanford, helping build out the firm's on-the-ground engineer deployment model. Since becoming CTO in early 2023, his public profile has grownand so has his influence in the national security space. In June, Sankar was tapped to join the U.S. Army Reserve's Executive Innovation Corps, a new initiative aimed at modernizing defense through private-sector expertise. About two-thirds of his Palantir holdings are in Class B shares, giving him 10x the voting rightsbut still well below the control retained by Karp, Thiel, and Cohen via Palantir's controversial three-class structure. But not everything is blue skies. Sankar offloaded nearly $370 million worth of shares in late 2024his largest sale evercontributing to a $4 billion insider selling spree across Palantir leadership last year. While he still holds options that could be worth over $210 million, those moves have raised fresh questions about timing and long-term confidence. With Q2 earnings due soon, investors are watching whether Palantir's operational momentum can keep pace with its soaring stockand whether the next leg up is powered by fundamentals or just hype. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
MercadoLibre misses profit estimates as Brazil free-shipping boost hurts margins
By Andre Romani SAO PAULO (Reuters) -Latin American e-commerce giant MercadoLibre on Monday posted a 1.5% dip in its second-quarter net profit from a year earlier, missing analysts' estimates, as increased free shipping in Brazil drove sales up but also hit margins. MercadoLibre, Latin America's largest company by market value, reported net income of $523 million for the quarter through the end of June, below the $596 million expected by analysts in an LSEG poll. MercadoLibre, based in Uruguay, operates an e-commerce platform and the fintech Mercado Pago, selling in nearly 20 countries throughout Latin America. Net revenue of $6.8 billion was up 34% year-on-year, beating the estimate of $6.7 billion, with sales measured by gross merchandise value rising 37% on a forex-neutral basis. In early June, MercadoLibre cut the threshold for purchases eligible for free shipping in Brazil, after also lowering shipping costs for companies and users selling on its platform in May, amid fierce competition in the country's e-commerce segment. Brazil, the firm's main market, together with Mexico helped MercadoLibre to increase total items sold by 31% in the quarter, the fastest pace year-on-year since mid-2021. However, that also hurt margins, said Chief Financial Officer Martin de los Santos. "We don't want to miss the growth opportunities ahead of us," he said in an interview. "That might generate some structural margin pressure, but we are very optimistic about the long-term trajectory of our profitability." Earnings before interest and taxes (EBIT) reached a record high of $825 million, but also missed the $869 million forecast. The EBIT margin stood at 12.2%, down from 14.3% a year earlier. The CFO said that among the main impacts on margins were investments in free shipping and related marketing, and growth in its so-called 1P business, which sells directly to customers. MercadoLibre's fintech arm grew its credit portfolio by 91% to $9.3 billion, while the 15-to-90-day default ratio fell 1.5 percentage points to 6.7%, the lowest since it started to release the figure seven years ago, the CFO said.
Yahoo
18 minutes ago
- Yahoo
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
SAN DIEGO, August 04, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia's digital transformation including technology, data and AI strategy and will serve as a member of the company's Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia. "We are thrilled to welcome Scott to Acadia," said Catherine Owen Adams. "Scott's extensive leadership in digital transformation, AI-driven innovation, and global IT operations across leading biopharmaceutical companies makes him an ideal fit for our organization. His proven ability to scale digital capabilities and drive business value will be instrumental as we continue to grow and evolve." Scott brings over 25 years of experience in the pharmaceutical and biotechnology industries, having held senior leadership roles at Genmab, Biogen, Zoetis, and Pfizer. Most recently, he served as Senior Vice President of Global Information Technology and Digital at Genmab, where he transformed the IT function into a full-scale digital organization, supporting the company's growth from 500 to 2,700 employees and from $750 million to over $3 billion in revenue. Throughout his career, Scott has led enterprise-wide digital and AI initiatives, implemented global ERP and cloud platforms, and driven operational efficiencies through agile methodologies and data analytics. He has also played key roles in major corporate transformations, including IPOs, spin-offs, and M&A integrations. "I am honored to join Acadia at such a pivotal time," said Scott Cenci. "The opportunity to contribute to a company that is deeply committed to investing in data, technology, and AI to accelerate innovation and improved patient care is incredibly exciting. I look forward to partnering with the team to advance Acadia's digital capabilities and support its mission to bring new therapies to patients." Scott holds an MBA in Management Information Systems from Seton Hall University and a BS in Computer Science and a minor in Mathematics from The College of New Jersey. He has served as an advisor to professional organizations and is an active member of the Osage Venture Partners Technology Advisory Board. Additionally, Scott has served as a speaker on topics such as Generative AI and digital transformation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. View source version on Contacts Investor Contact: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
